

- Bahn, R. S. (2010). "Graves' ophthalmopathy." *New England Journal of Medicine* 362(8): 726-738.
- Bartalena, L., L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, et al. (2008). "Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO." *European journal of endocrinology* 158(3): 273-285.
- Brasil, M. V. O. M., O. F. M. Brasil, R. P. Vieira, M. Vaisman and O. M. B. d. Amaral Filho (2005). "Tear film analysis and its relation with palpebral fissure height and exophthalmos in Graves' ophthalmopathy." *Arquivos Brasileiros de Oftalmologia* 68(5): 615-618.
- Çelik, I., S. Akalin and T. Erbaş (1995). "Serum levels of interleukin 6 and tumor necrosis factor- $\alpha$  in hyperthyroid patients before and after propylthiouracil treatment." *European journal of endocrinology* 132(6): 668-672.
- Ebihara, N., A. Matsuda, S. Nakamura, H. Matsuda and A. Murakami (2011). "Role of the IL-6 classic-and trans-signaling pathways in corneal sterile inflammation and wound healing." *Investigative ophthalmology & visual science* 52(12): 8549-8557.
- Fonseca, J., M. Santos, H. Canhao and E. Choy (2009). "Interleukin-6 as a key player in systemic inflammation and joint destruction." *Autoimmunity reviews* 8(7): 538-542.
- Gianoukakis, A. G., N. Khadavi and T. J. Smith (2008). "Cytokines, Graves' disease, and thyroid-associated ophthalmopathy." *Thyroid* 18(9): 953-958.
- Gupta, A., P. B. Sadeghi and E. K. Akpek (2009). "Occult thyroid eye disease in patients presenting with dry eye symptoms." *American journal of ophthalmology* 147(5): 919-923.
- Gupta, S. and R. Douglas (2011). "The pathophysiology of thyroid eye disease (TED): implications for immunotherapy." *Current opinion in ophthalmology* 22(5): 385.
- Hagan, S., E. Martin and A. Enríquez-de-Salamanca (2016). "Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine." *Epma Journal* 7(1): 1-20.
- Harris, M. A., T. Realini, J. P. Hogg and J. A. Sivak-Callcott (2012). "CT dimensions of the lacrimal gland in Graves orbitopathy." *Ophthalmic Plastic & Reconstructive Surgery* 28(1): 69-72.
- Huang, D., Q. Luo, H. Yang and Y. Mao (2014). "Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy." *Investigative ophthalmology & visual science* 55(8): 4935-4943.

- Huang, D., N. Xu, Y. Song, P. Wang and H. Yang (2012). "Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy." *Graefe's Archive for Clinical and Experimental Ophthalmology* 250(4): 619-625.
- Ing, E. and K. Abuhaleeqa (2007). "Graves' ophthalmopathy (thyroid-associated orbitopathy)." *Clin Surg Ophthalmol* 25: 386-392.
- José, J. C.-M., R. Rivera-Moscoso, A. F.-R. Jorge, J. Vargas-Sánchez, G. Ortega-Gutiérrez, et al. (2020). Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population. *Annales d'Endocrinologie*, Elsevier.
- Kahaly, G. J., S. Pitz, G. Hommel and M. Dittmar (2005). "Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy." *The Journal of Clinical Endocrinology & Metabolism* 90(9): 5234-5240.
- Kahaly, G. J., O. Shimony, Y. N. Gellman, S. D. Lytton, L. Eshkar-Sebban, et al. (2011). "Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin." *The Journal of Clinical Endocrinology & Metabolism* 96(2): 422-429.
- Khurana, A., S. Sunder, B. Ahluwalia and K. Malhotra (1992). "Tear film profile in Graves' ophthalmopathy." *Acta ophthalmologica* 70(3): 346-349.
- Kotwal, A. and M. Stan (2018). "Thyrotropin receptor antibodies—An overview." *Ophthalmic Plastic & Reconstructive Surgery* 34(4S): S20-S27.
- Krassas, G. E. and W. M. Wiersinga (2005). "Thyroid eye disease: current concepts and the EUGOGO perspective." *Thyroid international* 4: 3-21.
- Lacka, K., E. Manuszewska, I. Korczowska and J. K. Lacki (2007). "The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy." *Current eye research* 32(3): 291-297.
- Längericht, J., Krämer, I., & Kahaly, G. J. (2020). Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. *Therapeutic Advances in Endocrinology and Metabolism*, 11, 2042018820958335.
- Le Moli, R., L. Baldeschi, P. Saeed, N. Regensburg, M. P. Mourits, et al. (2007). "Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy." *Thyroid* 17(4): 357-362.
- Leszczynska, A., B. Molins, E. Fernández, A. Adán and S. Ortiz-Perez (2019). "Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab." *Graefe's Archive for Clinical and Experimental Ophthalmology* 257(10): 2307-2314.
- Maeda, K., Y. Ohara, M. Hashimoto and H. Ohguro (2008). "Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: Pre-or poststeroid pulse treatment." *Clinical ophthalmology (Auckland, NZ)* 2(3): 609.

- Mandić, J. J., A. Kozmar, S. Kusačić-Kuna, A. Jazbec, K. Mandić, et al. (2018). "The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis." *Graefe's Archive for Clinical and Experimental Ophthalmology* 256(4): 845-852.
- Marinó, M., E. Morabito, M. R. Brunetto, L. Bartalena, A. Pinchera, et al. (2004). "Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy." *Thyroid* 14(5): 403-406.
- Marcocci, C., Watt, T., Altea, M.A., Rasmussen, A.K., Feldt-Rasmussen, U., Orgiazzi, J. and Bartalena, L. 2012. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves orbitopathy: a questionnaire survey among members of the European Thyroid Association. *Eur J Endocrinol*, 166(2), pp.247-253.
- Modjtahedi, S. P., B. S. Modjtahedi, A. M. Mansury, D. Selva, R. S. Douglas, et al. (2006). "Pharmacological treatments for thyroid eye disease." *Drugs* 66(13): 1685-1700.
- Molnár, I. and C. Balazs (1997). "High circulating IL-6 level in Graves' ophthalmopathy." *Autoimmunity* 25(2): 91-96.
- Mu, P.-W., X.-X. Tang, Y.-N. Wang, S. Lin, M.-M. Wang, et al. (2020). "Comparison of two regimens for patients with thyroid-associated ophthalmopathy receiving intravenous methyl prednisolone: A single center prospective randomized trial." *Experimental and Therapeutic Medicine* 20(6): 1-1.
- Perros, P., M. Žarković, C. Azzolini, G. Ayvaz, L. Baldeschi, et al. (2015). "PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012." *British Journal of Ophthalmology* 99(11): 1531-1535.
- Said, E. A., Al-Reesi, I., Al-Shizawi, N., Jaju, S., Al-Balushi, M. S., Koh, C. Y., ... & Jeyaseelan, L. (2021). Defining IL-6 levels in healthy individuals: A meta-analysis. *Journal of Medical Virology*, 93(6), 3915-3924.
- Schiffman, J. S., M. Sales-Sanz, G. Rebolleda, A. F. Pass, R. A. Cruz, et al. (2013). "Thyroid orbitopathy." *Expert Review of Ophthalmology* 8(2): 191-206.
- Selter, J. H., A. I. Gire and S. Sikder (2015). "The relationship between Graves' ophthalmopathy and dry eye syndrome." *Clinical ophthalmology (Auckland, NZ)* 9: 57.
- Shen, J., Z. Li, W. Li, Y. Ge, M. Xie, et al. (2015). "Th1, Th2, and Th17 cytokine involvement in thyroid associated ophthalmopathy." *Disease markers* 2015.
- Sridhar, M. S. (2018). "Anatomy of cornea and ocular surface." *Indian journal of ophthalmology* 66(2): 190.
- Subekti, I., P. Soewondo, S. Soebardi, B. Darmowidjojo, D. S. Harbuwono, et al. (2019). "Practical Guidelines Management of Graves Ophthalmopathy." *Acta Medica Indonesiana* 51(4): 364-371.

- Ujhelyi, B., P. Gogolak, A. Erdei, V. Nagy, E. Balazs, et al. (2012). "Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines." *Thyroid* 22(4): 407-414.
- van Geest, R. J., I. V. Sasim, H. P. Koppeschaar, R. Kalmann, S. N. Stravers, et al. (2008). "Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study." *European journal of endocrinology* 158(2): 229-237.
- Villani, E., F. Viola, R. Sala, M. Salvi, C. Mapelli, et al. (2010). "Corneal involvement in Graves' orbitopathy: an in vivo confocal study." *Investigative ophthalmology & visual science* 51(9): 4574-4578.
- Weiler, D. L. (2017). "Thyroid eye disease: a review." *Clinical and experimental optometry* 100(1): 20-25.
- Willcox, M. D., P. Argüeso, G. A. Georgiev, J. M. Holopainen, G. W. Laurie, et al. (2017). "TFOS DEWS II tear film report." *The ocular surface* 15(3): 366-403.
- Xu, N., Y. Cui, D. Fu and F. Sun (2020). "Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids." *Journal of Endocrinological Investigation* 43(7): 901-910.
- Yang, M., Y. Chung, S. Lang, N. Yawata, L. L. Seah, et al. (2018). "The tear cytokine profile in patients with active Graves' orbitopathy." *Endocrine* 59(2): 402-409.
- Yoon, J. S., S. H. Choi, J. H. Lee, S. J. Lee and S. Y. Lee (2010). "Ocular surface inflammation, and nerve growth factor level in tears in active thyroid-associated ophthalmopathy." *Graefe's Archive for Clinical and Experimental Ophthalmology* 248(2): 271-276.
- Zang, S., K. Ponto and G. Kahaly (2011). "Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity." *The Journal of Clinical Endocrinology & Metabolism* 96(2): 320-332.